Search Bar & Filters
Found 1 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the levels of plasma bimekizumab after subcutaneous administration in children aged 2 to under 18 years with active juvenile idiopathic arthritis subtypes, specifically enthesitis-related arthritis including juvenile-onset ankylosing spondylitis and juvenile psoriatic arthritis. This Phase 3 open-label trial aims to understand the pharmacokinetics and safety of bimekizumab in this pediatric population. Participants will receive weight-based doses of bimekizumab at scheduled times. The study is a single-arm design where all participants receive the investigational drug. The initial treatment period lasts up to 16 weeks, during which plasma concentrations of bimekizumab are monitored closely. Following this, there is a safety follow-up period lasting up to 141 weeks to track treatment-emergent adverse events and other safety parameters. Throughout the study, participants will undergo various assessments including vital signs, blood tests for biochemistry and hematology, growth measurements, and evaluations for injection site pain. Disease activity and response are measured using standardized pediatric arthritis scores. Researchers will also monitor for antibodies against bimekizumab and record any serious or specific safety events. The total participation may extend over several years to ensure long-term safety and treatment effects are observed.